The Trump Administration's request for information regarding the reduction of out-of-pocket prices for medication has been the most important topic at the intersection of policy and healthcare of 2018. Creating a blueprint of action to address what policies could be enacted to reduce out-of-pocket costs for patients, the Administration carefully scrutinized PBMs, drug manufacturers, and a variety of anti-transparency measures such as gag clauses. Their request garnered well over 2,000 responses at the Department of Health and Human Services from a variety of concerned stakeholders on all sides of the issue. Secretary Alexander Azar has appeared in the press and before Congress to bring the issue of sky-rocketing costs for patients to light in the public sphere. 

​

Attached below are the comments co-authored by the Coalition to Protect Patient Choice with Consumers Union, Consumer Action,  and US PIRG.

 

Additionally, there are comments and letters submitted by: Patients for Affordable Drugs (P4AD), I-MAK, Alliance for Transparent and Affordable Prescriptions (ATAP), KEI, PhRMA, National Business Group on Health (NBGH), Coalition of State Rheumatology Organizations (CSRO), and Families USA and Public Citizens.